Table 1.
Patient characteristics and characterization of cell products.
| Case Number | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | ||
| Sex (M/F) | M | M | M | M | M | F | M | M | |
| Age (years) | 54 | 46 | 32 | 64 | 38 | 52 | 51 | 50 | |
| BMI (kg/m2) | 23.3 | 25.1 | 26.8 | 26.8 | 28.41 | 23.8 | 25.4 | 20.6 | |
| Hypertension (Y/N) | N | N | N | Y | N | N | N | N | |
| Diabetes mellitus (Y/N) | N | N | N | N | N | N | N | N | |
| Smoking history (Y/N) | N | N | Y | N | N | N | N | N | |
| Duration of LBP (month) | 120 | 36 | 37 | 11 | 60 | 12 | 49 | 48 | |
| Implanted disc level | L4/5 | L4/5 | L4/5 | L4/5 | L4/5 | L4/5 | L4/5 | L4/5 | |
| Preoperative VAS | 9 | 7 | 6 | 5 | 9 | 6 | 4 | 6 | |
| Preoperative ODI (%) | 45 | 56 | 35 | 45 | 70 | 45 | 35 | 35 | |
| Preoperative modified Pfirrmann grade | Ⅴ | Ⅳ | Ⅵ | Ⅴ | Ⅳ | Ⅳ | Ⅲ | VII | |
| Cell number in a vial (×107) | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |
| Injected cell number with 400 μL of hyaluronic acid (×106) | 6.0 | 6.0 | 6.0 | 6.0 | 6.0 | 6.0 | 6.0 | 6.0 | |
| Cell viability (%) | 91.5 | 95.86 | 96.55 | 95.8 | 96.55 | 92.76 | 96.46 | 95.9 | |
| Cell surface marker | CD44 (%) | 87.2 | 100 | 100 | 99.9 | 99.7 | 100 | 99.6 | 98.4 |
| CD73 (%) | 97.9 | 98.9 | 99 | 98.7 | 96.8 | 87.4 | 94.1 | 94.4 | |
| CD45 (%) | 1.6 | 1.4 | 0.8 | 1 | 0.6 | 0.5 | 0.8 | 0.5 | |
M: male; F: female; BMI: body mass index; Y: yes; N: No; LBP: low back pain; VAS: visual analogue scale; ODI: Oswestry Disability Index.